Premium
The effect of anti‐CD40 ligand in immune thrombocytopenic purpura
Author(s) -
Patel Vivek L.,
Schwartz Joseph,
Bussel James B.
Publication year - 2008
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2008.07039.x
Subject(s) - cd40 , medicine , thrombocytopenic purpura , refractory (planetary science) , autoantibody , immune system , immunology , monoclonal antibody , gastroenterology , antibody , biology , biochemistry , cytotoxic t cell , astrobiology , in vitro
Summary Immune thrombocytopenic purpura (ITP) is mediated by antiplatelet autoantibodies possibly involving CD40:CD40L co‐stimulation. Two humanized anti‐CD40L monoclonal antibodies, hu5c8 and IDEC‐131, were evaluated in 46 patients with chronic refractory ITP. Fifteen patients were treated with 20 mg/kg of hu5c8: four (27%) had complete responses (CR) and two (13%) had partial responses (PR). Three responders to hu5c8 were successfully retreated with IDEC‐131, demonstrating its efficacy. Thirty‐one subsequent patients were treated with 5–20 mg/kg per infusion of IDEC‐131: five (16%) responded (one CR and four PR). The 24% (11/46) overall response rate demonstrates the potential role of CD40‐CD40L in the pathogenesis of ITP.